Oseltamavir: Difference between revisions
| Line 38: | Line 38: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 1-3 hrs (oseltamivir); 6-10hrs oseltamivir carboxylate) | *Half-life: 1-3 hrs (oseltamivir); 6-10hrs oseltamivir carboxylate) | ||
*Metabolism: | *Metabolism: hepatic | ||
*Excretion: | *Excretion: urine/stool | ||
*Mechanism of Action: competitive inhibition of influenza virus neuraminidase enzyme, effectively halting viral release from infected cells and passing through mucus membranes. | *Mechanism of Action: competitive inhibition of influenza virus neuraminidase enzyme, effectively halting viral release from infected cells and passing through mucus membranes. | ||
Revision as of 03:38, 1 November 2017
General
- Type: Antiviral - neuraminidase inhibitor
- Dosage Forms: capsule (30, 45, 75mg), powder for PO susp (6mg/mL)
- Common Trade Names: Tamiflu
Adult Dosing
Influenza
75mg PO BID x5d
Pediatric Dosing
5 day course
- 1-8 months: 3mg/kg PO BID
- 9-23 months: 3.5mg/kg PO BID
- 2-12 years:
- <15kg: 30mg PO BID
- 16-23kg: 45mg PO BID
- 24-40kg: 60mg PO BID
- >40kg: 75mg PO BID
Special Populations
- Pregnancy Rating: Category C
- Lactation: Unknown; caution required
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 1-3 hrs (oseltamivir); 6-10hrs oseltamivir carboxylate)
- Metabolism: hepatic
- Excretion: urine/stool
- Mechanism of Action: competitive inhibition of influenza virus neuraminidase enzyme, effectively halting viral release from infected cells and passing through mucus membranes.